Sign In
Buy DOCS
$20.91
-0.330 (-1.55%)
At Close: Jul 31, 2026
Doximity Announces Fiscal 2026 Second Quarter Financial Results
04:01pm, Thursday, 06'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30,
S-DOCS DOCUMENT AUTOMATION SOLUTION BECOMES HUBSPOT APP PARTNER WITH A CERTIFIED INTEGRATION
09:00am, Thursday, 06'th Nov 2025
/PRNewswire/ -- Today, S-Docs announced that it has joined HubSpot's App Partner Program with a certified integration for the HubSpot platform. HubSpot, the
Sumitomo Mitsui Trust Group Inc. Has $715,000 Stock Position in Doximity, Inc. $DOCS
04:11am, Saturday, 01'st Nov 2025
Sumitomo Mitsui Trust Group Inc. increased its position in shares of Doximity, Inc. (NASDAQ: DOCS) by 3.1% during the second quarter, according to its most recent Form 13F filing with the Securities a
Doximity (DOCS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:07am, Thursday, 30'th Oct 2025
Doximity (DOCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Doximity (DOCS) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Wednesday, 29'th Oct 2025
Doximity (DOCS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Wednesday, 29'th Oct 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Buy These 5 Health and Fitness Stocks for a Stable Portfolio in Q4
09:05am, Wednesday, 29'th Oct 2025
DOCS, PLNT, UNFI, PTON and PFGC are five health and fitness stocks with growth potential, diversified revenue and resilient demand.
Doximity (DOCS) Surpasses Market Returns: Some Facts Worth Knowing
07:16pm, Monday, 27'th Oct 2025
Doximity (DOCS) closed at $68.5 in the latest trading session, marking a +2.48% move from the prior day.
Cullen Frost Bankers Inc. Has $88,000 Holdings in Doximity, Inc. $DOCS
04:55am, Sunday, 26'th Oct 2025
Cullen Frost Bankers Inc. lifted its position in shares of Doximity, Inc. (NASDAQ: DOCS) by 29.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securit
Dr Martens back on its feet
09:30am, Friday, 24'th Oct 2025
It has been a tough couple of years for Dr Martens PLC (LSE:DOCS), but Berenberg thinks the bootmaker is lacing up for recovery. The broker keeps its 'buy' rating and 114p price target, saying the com
Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights
07:40am, Friday, 24'th Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Doximity Inc. (NYSE: DOCS) breached their fiduciary duties to share
Doximity, Inc. (NASDAQ:DOCS) Given Average Recommendation of “Hold” by Brokerages
02:39am, Thursday, 23'rd Oct 2025
Doximity, Inc. (NASDAQ: DOCS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twenty-two ratings firms that are covering the firm, Marketbeat reports. Two analysts ha
Doximity to Release Fiscal 2026 Second Quarter Results on November 6, 2025
04:01pm, Thursday, 16'th Oct 2025
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter
Here's Why Doximity (DOCS) Fell More Than Broader Market
07:15pm, Friday, 10'th Oct 2025
In the closing of the recent trading day, Doximity (DOCS) stood at $65.61, denoting a -9.59% move from the preceding trading day.
Can Doximity's New AI Suite Drive the Growth It Needs?
10:16am, Thursday, 02'nd Oct 2025
DOCS reports stronger Q1 results and is betting on its new AI suite -- Scribe, GPT, and Pathway -- to drive its next growth phase.
